Trial Profile
Prospective Observational Study on Predictors of Early On-treatment Response and Sustained Virological Response in a Cohort of Treatment naive HCV-infected Patients Treated With Pegylated Interferons.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Oct 2016
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Peginterferon alfa-2b (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms PROPHESYS-2
- Sponsors Roche
- 04 Apr 2016 Time frame for Virological Response changed from weeks 4 and 12, and 12 and 24 weeks after end of treatment to 24 weeks after end of treatment.
- 15 Feb 2012 Actual patient number changed from 2271 to 2272 as reported by ClinicalTrials.gov.
- 17 Jan 2012 Actual patient number changed from 2273 to 2271 as reported by ClinicalTrials.gov.